Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Globalization, Three Quarters of Serious Issues FDA Found Were in US

This article was originally published in The Gold Sheet

Executive Summary

FDA inspection results data show that even as the agency responded to the threat of poor drug quality abroad in fiscal years 2009-2014, it was more successful at finding serious quality issues during its much more numerous domestic inspections. Asian inspections were somewhat more likely to identify serious issues than US ones, while European inspections were much less likely to raise any, and neither identified nearly as many.

Advertisement

Related Content

Indian CEOs On Plugging Quality Gaps: Yes We Can
FDA Mutual Reliance with EU on Inspections Is Slow Going
Hamburg Promises Quicker Enforcement as FDA Spews Warning Letters
Electronic Registration to Aid FDA's Quest for Enhanced Global Oversight

Topics

Advertisement
UsernamePublicRestriction

Register

PS000961

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel